Physician profile
Isidro B Salusky
NPI 1861501546
$47,309.06
in general payments reported to CMS, 2019-2025
10 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Pediatric Nephrology provider received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $10K · 2021: $2,600 · 2022: $13K · 2023: $685 · 2024: $58.46 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.91 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $40,400.05 | 2019-2025 | Crysvita |
| Akebia Therapeutics INC | $5,442.59 | 2019-2025 | Auryxia, Vafseo |
| Amgen INC. | $926.24 | 2019-2023 | Parsabiv |
| Kyowa Kirin, INC. | $197.66 | 2023-2025 | Crysvita |
| Ardelyx, INC. | $143.53 | 2023 | Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $80.80 | 2019 | |
| Apellis Pharmaceuticals, INC. | $62.12 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $29.56 | 2024 | Oxlumo |
| Novo Nordisk INC | $26.51 | 2025 | Rivfloza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isidro Salusky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.